Update on lipids and mitochondrial function: Impact of dietary n-3 polyunsaturated fatty acids

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 15, Issue 2, 2012, Pages 122-126

  Stanley, William C ^a   Khairallah, Ramzi J ^a   Dabkowski, Erinne R ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

docosahexanoic acid; membrane phospholipids; mitochondria; n 3 polyunsaturated fatty acid

Indexed keywords

ARACHIDONIC ACID; CARDIOLIPIN; DOCOSAHEXAENOIC ACID; LIPID; OMEGA 3 FATTY ACID;

CELL DEATH; FAT INTAKE; HEART MITOCHONDRION; HEART PROTECTION; HUMAN; LIPID COMPOSITION; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE; NONHUMAN; PHOSPHOLIPID MEMBRANE; REVIEW;

ARACHIDONIC ACID; CARDIOLIPINS; DIETARY FATS; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; HUMANS; LIPID METABOLISM; MITOCHONDRIA, HEART; MITOCHONDRIAL MEMBRANES; PHOSPHOLIPIDS;

TETRA;

EID: 84857055262     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0b013e32834fdaf7     Document Type: Review

References (30)

1. LopaschukGD, Ussher JR, Folmes CD, et al. Myocardial fatty acid metabolism in health and disease. Physiol Rev 2010; 90:207-258.
2. Madrazo JA, Kelly DP. The PPAR trio: Regulators of myocardial energy metabolism in health and disease. J Mol Cell Cardiol 2008; 44:968-975.
3. Noy N. Ligand specificity of nuclear hormone receptors: Sifting through promiscuity. Biochemistry 2007; 46:13461-13467. (Pubitemid 350214357)
4. Schlame M, Towbin JA, Heerdt PM, et al. Deficiency of tetralinoleoylcardiolipin in Barth syndrome. Ann Neurol 2002; 51:634-637.
5. Minkler PE, Hoppel CL. Separation and characterization of cardiolipin molecular species by reverse-phase ion pair high-performance liquid chromatography-mass spectrometry. J Lipid Res 2010; 51:856-865. Presents a novel method for measuring cardiolipin, and provide the potentially important observation that mice have a profoundly different cardiolipid fatty acyl side chain composition than seen in humans, dogs and mice.
6. Sparagna GC, Lesnefsky EJ. Cardiolipin remodeling in the heart. J Cardiovasc Pharmacol 2009; 53:290-301.
7. Schlame M, Kelley RI, Feigenbaum A, et al. Phospholipid abnormalities in children with Barth syndrome. J Am Coll Cardiol 2003; 42:1994-1999. (Pubitemid 37485578)
8. Acehan D, Vaz F, Houtkooper RH, et al. Cardiac and skeletal muscle defects in a mousemodel of human Barth syndrome. J Biol Chem2011; 286:899-908. Presents a novel mouse model of tafazzin deficiency which should prove very useful for studying cardiolipidin physiology and the pathology of Barth syndrome.
9. Sparagna GC, Johnson CA, McCune SA, et al. Quantitation of cardiolipin molecular species in spontaneously hypertensive heart failure rats using electrospray ionization mass spectrometry. J Lipid Res 2005; 46:1196-1204. (Pubitemid 43109834)
10. Sparagna GC, Chicco AJ, Murphy RC, et al. Loss of cardiac tetralinoleoyl cardiolipin in human and experimental heart failure. J Lipid Res 2007; 48:1559-1570. (Pubitemid 47312017)
11. Rosca M, Minkler P, Hoppel CL. Cardiac mitochondria in heart failure: Normal cardiolipin profile and increased threonine phosphorylation of complex IV. Biochim Biophys Acta 2011; 1807:1373-1382. Analysis of cardiolipin composition and content of cardiac mitochondria from dogs with heart failure, showing normal cardiolipin content and compositon despite severe mitochondrial respiratory dysfunction.
12. Rosca MG, Vazquez EC, Kerner J, et al. Cardiac mitochondria in coronary microembolization-induced heart failure: Decrease in respirasomes and oxidative phosphorylation. Cardiovasc Res 2008; 80:30-39.
13. Pepe S, Tsuchiya N, Lakatta EG, Hansford RG. PUFA and aging modulate cardiac mitochondrial membrane lipid composition and Ca2+ activation of PDH. Am J Physiol 1999; 276:H149-H158. (Pubitemid 29065633)
14. O'Shea KM, Khairallah RJ, Sparagna GC, et al. Dietary omega-3 fatty acids alter cardiac mitochondrial phospholipid composition and delay Ca2+induced permeability transition. J Mol Cell Cardiol 2009; 47:819-827.
15. Duda MK, O'Shea KM, Stanley WC. omega-3 polyunsaturated fatty acid supplementation for the treatment of heart failure: Mechanisms and clinical potential. Cardiovasc Res 2009; 84:33-41.
16. Duda MK, O'Shea KM, Lei B, et al. Dietary supplementation with omega-3 PUFA increases adiponectin and attenuates ventricular remodeling and dysfunction with pressure overload. Cardiovasc Res 2007; 76:303-310. (Pubitemid 350198598)
17. Duda MK, O'Shea KM, Tintinu A, et al. Fish oil, but not flaxseed oil, decreases inflammation and prevents pressure overload-induced cardiac dysfunction. Cardiovasc Res 2009; 81:319-327.
18. Shah KB, Duda MK, O'Shea KM, et al. The cardioprotective effects of fish oil during pressure overload are blocked by high fat intake: Role of cardiac phospholipid remodeling. Hypertension 2009; 54:605-611.
19. Pepe S, McLennan PL. Cardiac membrane fatty acid composition modulates myocardial oxygen consumption and postischemic recovery of contractile function. Circulation 2002; 105:2303-2308. (Pubitemid 34535342)
20. Peoples GE, McLennan PL, Howe PR, Groeller H. Fish oil reduces heart rate and oxygen consumption during exercise. J Cardiovasc Pharmacol 2008; 52:540-547.
21. Demaison L, Sergiel JP, Moreau D, Grynberg A. Influence of the phospholipid n-6/n-3 polyunsaturated fatty acid ratio on the mitochondrial oxidative metabolism before and after myocardial ischemia. Biochim Biophys Acta 1994; 1227:53-59. (Pubitemid 24320385)
22. Khairallah RJ, Sparagna GC, Khanna N, et al. Dietary supplementation with docosahexaenoic acid, but not eicosapentaenoic acid, dramatically alters cardiac mitochondrial phospholipid fatty acid composition and prevents permeability transition. Biochim Biophys Acta 2010; 1797:1555-1562. Demonstrates that dietary supplementation with DHA, but not EPA, profoundly remodels mitochondrial phospholipids and delays Ca2+-induced permeability transition.
23. Khairallah RJ, O'Shea KM, Brown BH, et al. Treatment with docosahexaenoic acid, but not eicosapentaenoic acid, delays Ca2+-induced mitochondria permeability transition in normal and hypertrophied myocardium. J Pharmacol Exp Ther 2010; 335:155-162. Extends the previous observation that dietary supplementation with DHA delays Ca2+-induced mitochondrial permeability transition using a model of cardiac hypertrophy caused by pressure overload.
24. Yamaoka S, Urade R, Kito M. Mitochondrial function in rats is affected by modification of membrane phospholipids with dietary sardine oil. J Nutr 1988; 118:290-296. (Pubitemid 18079079)
25. Grimsgaard S, Bonaa KH, Hansen JB, Nordoy A. Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerollowering effects but divergent effects on serum fatty acids. Am J Clin Nutr 1997; 66:649-659. (Pubitemid 27366792)
26. Mori TA, Woodman RJ. The independent effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans. Curr Opin Clin Nutr Metab Care 2006; 9:95-104. (Pubitemid 44090031)
27. Igarashi M, Ma K, Chang L, et al. Rat heart cannot synthesize docosahexaenoic acid from circulating alpha-linolenic acid because it lacks elongase-2. J Lipid Res 2008; 49:1735-1745.
28. Ricchelli F, Sileikyte J, Bernardi P. Shedding light on the mitochondrial permeability transition. Biochim Biophys Acta 2011; 1807:482-490. Timely review on the biochemistry of mitochondrial permeability transition
29. Halestrap AP. A pore way to die: The role of mitochondria in reperfusion injury and cardioprotection. Biochem Soc Trans 2010; 38:841-860. Overview of the role of mitochondrial dysfunction in cardiac injury, with an emphasis on mitochondrial permeability transition pore opening.
30. Anderson EJ, Lustig ME, Boyle KE, et al. Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest 2009; 119:573-581.